Business Context and Reporting Period
Company: GRI Bio, Inc. (GRI)
Reporting Period: Quarter ended June 30, 2024 (Q2 2024)
Business Overview: GRI Bio is a clinical-stage biopharmaceutical company developing therapies for inflammatory, fibrotic, and autoimmune disorders. Its lead candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T cells for idiopathic pulmonary fibrosis (IPF). The company is currently conducting a Phase 2a biomarker study for IPF, with interim data expected in Q4 2024.
Corporate Status: The company is an emerging growth company and a smaller reporting company. It recently completed a reverse merger with Vallon Pharmaceuticals, Inc. in April 2023 and executed reverse stock splits in January and June 2024 to maintain Nasdaq listing compliance.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,137) | $(8,896) |
| Operating Expenses | $4,153 | $6,923 |
| Cash and Cash Equivalents (End of Period) | $6,353 | $4,799 |
| Accumulated Deficit | $(35,670) | $(27,392) |
| Stockholders' Equity | $4,719 | $4,038 |
Cash Flow (Six Months Ended June 30, 2024):
- Operating Activities: $(4,344) used
- Investing Activities: $0 used
- Financing Activities: $8,889 provided (primarily from equity offerings)
- Net Increase in Cash: $4,545
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately 53% to $4.1 million for the six months ended June 30, 2024, compared to $8.9 million in the prior year period. This improvement is largely due to the absence of significant interest expense from Bridge Notes (amortization of debt discounts) in the current period, which totaled $2.1 million in the prior year.
- Operating Expenses: Total operating expenses decreased by $2.8 million to $4.2 million. General and Administrative (G&A) expenses dropped significantly by $3.6 million, driven by the completion of the Merger and reduced professional fees (legal, accounting, investment banking). Research and Development (R&D) expenses increased by $0.8 million to $1.8 million due to continued development of GRI-0621.
- Liquidity Position: Cash balances increased from $1.8 million at year-end 2023 to $6.4 million at June 30, 2024, following multiple equity financings in February and June 2024.
- Warrant Liability: The warrant liability was fully extinguished or reclassified, resulting in a $3,000 gain on change in fair value for the six months ended June 30, 2024, compared to a $122,000 gain in the prior year.
Outlook, Risks, and Management Commentary
Capital Resources and Going Concern: Management states there is substantial doubt about the company's ability to continue as a going concern for one year from the issuance of the financial statements. While current cash ($6.4 million) is projected to fund operations into the first quarter of 2025, the company will require substantial additional funding to continue clinical trials and operations.
Financing Activities:
- February 2024 Offering: Raised net proceeds of $4.4 million via common stock and pre-funded warrants.
- June 2024 Offering: Raised net proceeds of $3.2 million via common stock and pre-funded warrants.
- ATM Offering: Established an At-The-Market facility with H.C. Wainwright & Co., LLC. As of June 30, 2024, $1.0 million in gross proceeds were raised. The facility was subsequently increased to $2.6 million in July 2024.
Nasdaq Compliance: The company previously received notices regarding deficiencies in stockholders' equity and minimum bid price. Through the equity offerings and reverse stock splits, the company has cured the stockholders' equity deficiency and regained compliance with the minimum bid price rule as of July 2024.
Risks:
- Dependence on successful clinical trial outcomes for GRI-0621 and GRI-0803.
- Need for additional capital; failure to secure financing could force reduction or cessation of operations.
- High dilution risk due to the structure of recent financings involving pre-funded warrants and common warrants.
Investor Verification Checklist
- Cash Runway: Verify the specific burn rate and confirm the "first quarter of 2025" liquidity projection given the substantial doubt disclosure.
- Dilution Impact: Review the terms of the Series B and Series C warrants (exercise prices of $14.30 and $1.83 respectively) and the pre-funded warrants to understand potential future share count expansion.
- Clinical Milestones: Monitor the timeline for the Phase 2a biomarker study interim data (expected Q4 2024) and topline results (expected Q1 2025).
- ATM Utilization: Track the utilization of the At-The-Market offering facility, which was recently expanded to $2.6 million.
- Stock Split History: Note the multiple reverse stock splits (1-for-7 in Jan 2024, 1-for-13 in June 2024) and ensure share counts in financial statements are adjusted accordingly.